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Summary
Purpose: The linkage of human T-cell leukemia virus type
1 (HTLV-1) to fatal diseases is a well known fact for many
years. However, there has been no significant progress in the
field of the treatment that can lead to the development of a
successful vaccine. Furthermore, there are no means of assessing the risk of disease and its prognosis in the infected
people.

immunogens was done with the help of ABCPred and Immune Epitope Database.

Results: The results showed that the identified epitopes might
be protective immunogens with high conservancy and potential of inducing both protective neutralizing antibodies and Tcell responses. The peptides “PSQLPPTAPPLLPHSNLDHI”,
“PCPNLVAYSSYHATY”, and “YHATYSLYLF”, were 100%
Methods: The current study has taken the cognizance of the conserved among different isolates from far and wide separatimportance of host’s immune response in reducing the risk of ed countries, suggesting negligible antigenic drift in HTLV-1.
infectious diseases to carry out immunoinformatics driven
Conclusions: Overall, the mentioned epitopes are soluble,
epitope screening strategy of vaccine candidates against
non-toxic suitable candidates for the development of vacHTLV-1. In this study, a genetic variability and HLA districine against HTLV-1 and warrant further investigation and
bution analysis among the documented HTLV-1 genotypes
experimental validation.
I, II, III, IV, V & VI was performed to ensure the coverage
of the vast majority of population, where vaccine would be Key words: HTLV-1, immunity, immunoinformatics, oncoemployed. The meticulous screening of effective dominant genic virus, peptide vaccine

Introduction
HTLV-1 belongs to delta retrovirus family and
other members of this family are simian T-lymphotrophic virus type 1 (STLV-1) and bovine leukemia
virus (BLV) [1]. HTLV-1 was first reported in a cell
line derived from a patient with cutaneous T-cell
lymphoma in 1980 [2]. The symptoms of HTLV-1

infection do not appear in the majority of people,
whereas in some people it causes severe problems
like neoplastic diseases: Adult T-cell Lymphoma
(ATL), Cutaneous T-cell Lymphoma [3], inflammatory syndromes: HAM/TSP [4], uveitis [5] and opportunistic infections: dermatitis, lymphadentis,
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Sjogren’s syndrome [6]. ATL and HAM/TSP are the
most predominant among them. ATL has 5 different
clinical stages: asymptomatic carrier state, preleukemic state, chronic/smoldering ATL, lymphoma
type ATL and acute ATL [7]. HTLV-I infects T-cells,
B-cells, dendritic cells, monocytes, and endothelial
cells equally, yet the virus has preferential tropism
for CD4 T-cells [8]. HTLV-1, a single-stranded diploid RNA virus, is 9,030–9,040 nucleotides long
and contains two flanking long terminal repeat
(LTR) sequences [9] and is packaged in the viral
core with the viral nucleocapsid protein (p15 NC).
NC is enclosed in capsid (p24 CA) and matrix (p19
MA) proteins. Similar to the other retroviruses, the
HTLV-1 genome encodes the structural proteins
‘Gag’ (NC, CA, and MA) and ‘Env’, and the enzymatic ‘Pol’ proteins RT, Rnase H (RH), integrase (IN),
and protease. The env gene encodes two subunit
proteins: (SU) gp46 and transmembrane (TM) gp21
[10]. The gp46 confers cell receptor-binding activity. The fusion of receptor protein is performed by
gp21. HTLV-I ‘Env’ proteins are genetically highly
conserved among isolates, with very low variability
(1 to 8%) within their amino acid sequences [11,12].
On the other hand, the cellular entry of HTLV-1
involves three host cell surface proteins: glucose
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transporter 1 (GLUT1), neuropilin-1 (NRP-1) and
heparan sulfate proteoglycans (HSPG) [13], leading to a multi-receptor model host entry for HTLV1 [14,15]. The CTD of HTLV-1 SU interacts with
HSPGs during the initial attachment phase. This
improves the possibility and strength of binding
of HTLV-1 SU with NRP-1. The binding of HTLV-I
SU to NRP-1 leads to a conformational change, resulting in exposure of the GLUT1- binding domain.
Finally, the interaction of SU with GLUT1 activates
the translocation of TM gp21 that contributes in
the fusion mechanism [1]. HTLV-1 virus has six
known genotypes (HTLV-1a-g), distributed worldwide [3].
Comprehensive knowledge of the adaptive immune system is required for the development of
epitope-based vaccines. TH cells and TC cells can
recognize antigen when bound with major histocompatibility Complex (MHC) class II and I molecule, respectively [15,16]. MHC is a membrane
glycoprotein. In humans, it is also known as the
human leukocyte antigen (HLA) and is extremely
polymorphic in nature. The HLA molecules may
bind to an array of antigenic linear epitopes derived
from antigen processing, which initiate an immune
response. However, HLA binding alone does not en-

Figure 1. Schematic representation of the entire methodology adopted in this work.
JBUON 2018; 23(5): 1515
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sure the generation of T-cell immune response. The
different HLA alleles have varying peptide binding specificity among ethnic populations. It has
been reported that only few HLA supertypes can
cover the majority of alleles, where diverse members of a supertype bind similar peptides; these
similar peptides are called super antigens. Recently, eighteen major HLA class I supertypes (HLAHLA- A*0101, A*03:01, A*26:01, A*02:01, A*11:01,
A*68:01, B*08:01, B*37:01, B*07:02, B*14:02,
B*27:05, B*38:01, B*39:01, B*40:02, B*44:02,
B*48:01, B*49:01, B*51:01,) and six HLA class II supertypes (DRB1*01:01, DRB1*03:01, DRB1*04:01,
DRB1*07:01, DRB1*07:07, DRB1*15:01) have been
determined by comparing peptide-binding data
[17]. The problem of HLA allele’s population coverage and the chance of antigen escape due to antigenic drift or shift may be overcome by the binding
of peptides exhibiting super antigenic property to
a maximum number of HLA alleles with their conserved nature.
The present study has been designed for a meticulous analysis of predicted HLA binding peptides of HTLV-1 viral proteins of all the isolates.
The schematic diagram of the entire methodology
adopted in this work has been given in Figure 1.

antigens [18]. The server is based on Auto Cross Covariance (ACC) conversion of protein sequences into uniform
vectors of principal amino acid properties. It is being
considered as the first server predicting the protective
antigens in an alignment-independent manner.
The crystal or NMR structure of viral envelop protein was not available in Protein Data Bank (PDB), thus
selected sequences (from UniProtKB Database) were
used to develop the three-dimensional (3D) structure.
In order to build the 3D model, I-TASSER online server
[19] was used, which employs a fragment based method
for the modeling of the protein structure. The server predicted five models along with their C-score. The models
with highest C-score value, which is directly proportional to the confidence level of the model were selected.
The modeled structures were validated by the approach
of Ramachandran Plot using RAMPAGE [20]. Furthermore, the generated model was submitted to ModRefiner for atomic level high resolution protein structure
refinement.
Multiple sequence alignment
Using ClustalW (www.ebi.ac.uk/clustalw) multiple
sequence alignment program, best match (conserved
regions) for the selected sequences were calculated.
ClustalW is a multiple sequence alignment program
for DNA or Proteins. It calculates the best matches for
the selected sequences & arranges them in order of the
identities, similarities & differences seen.

Methods

Epitope prediction

Retrieval of protein sequences

Humoral immunity associated epitope prediction

The protein sequence ODS of Envelop glycoprotein
of six strains of Human T Lymphotropic Virus-I: Japan
MT-2 subtype A (ENV_HTL1M Envelope glycoprotein
gp62, P23064), Carribbea HS-35 subtype A (ENV_HTL1C
Envelope glycoprotein gp62, P14075), Melanesia mel5
subtype C (ENV_HTL1L Envelope glycoprotein gp62,
P0C212), Japan ATK-1 subtype A (ENV_HTL1A Envelope glycoprotein gp62, P03381), Zaire EL subtype B
(ENV_HTL1F Envelope glycoprotein gp62, Q03817) and
Caribbea CH subtype A (ENV_HTL1N Envelope glycoprotein gp62, Q03816) were retrieved from UniProtKB
Database (www.uniprot.org). The retrieved sequences
were used for various bioinformatics approaches such
as 3D-structure prediction, antigenicity assessment, and
epitope prediction.

For all of the six strains of HTLV-I, B-cell epitopes
were predicted using ABCPred online server (www.
imtech.res.in/abcpred), selecting the threshold 1.0 and
window length 20. The server is based on informationprocessing paradigm “neural network” inspired by
the mammalian brain. All the predicted epitopes were
ranked as per their respective scores. Higher score of
the peptides depicted the greater probability to be the
most suitable (immunogenic) epitope for the human
B-Lymphocytes.

Immunogenicity prediction of viral protein and structural
analysis
An antigen, which can be recognized by the immune system is called Immunogenic. VaxiJen v2.0
server [18] (http://www.ddg-pharmfac.net/vaxijen/VaxiJen/VaxiJen.html) was used for analyzing ‘Env’ protein
immunogenicity of HTLV-1 of all the genotypes from
different geographical areas by finding the best potential
candidate immunogen epitope. VaxiJen is a web server
to predict the protective antigens, tumor antigens and
subunit vaccines, with an accuracy of approximately 70
to 89% for the discrimination between antigens and nonJBUON 2018; 23(5): 1516

CD4+ and CD8+ epitope prediction
The peptides capable of stimulating T-cell epitopes
bind to MHC molecules. Most important attribute of
MHC molecules is their allelic polymorphism. The ImMunoGeneTics/HLA (IMGT) database listed 3,411 human leukocyte antigens (HLA) class-I and 1,222 HLA
class II molecules in July 2010 [21].
Envelop protein sequences of all the six strains
were analyzed for the screening of possible dominant
T cell epitopes using immunoinformatics tool IEDB online server (www.iedb.org). MHC-I binding and MHC-II
binding resources available in IEDB were used for the
binding analysis of all the possible peptides of 18 class
I HLA alleles: A*0101, HLA-A*03:01, A*26:01, A*02:01,
A*11:01, A*68:01, B*08:01, B*37:01, B*07:02, B*14:02,
B*27:05, B*38:01, B*39:01, B*40:02, B*44:02, B*48:01,
B*49:01, B*51:01, and 6 class II HLA alleles: DRB1*01:01,

In silico epitope prediction and HLA distribution analysis of HTLV-I
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Table 1. Overall immunogenecity prediction of all isolates of HTLV-I
Strain

UniProt ID

Threshold

Overall antigen prediction

Antigen

P23064

0.4

0.5004

Probable-Antigen

Caribbea HS-35 subtype A

P14075

0.4

0.5161

Probable-Antigen

Melanesia mel5 subtype C

P0C212

0.4

0.5015

Probable-Antigen

Japan ATK-1 subtype A

P03381

0.4

0.4928

Probable-Antigen

Zaire EL subtype B

Q03817

0.4

0.4830

Probable-Antigen

Caribbea CH subtype A

Q03816

0.4

0.4978

Probable-Antigen

Japan MT-2 subtype A

DRB1*03:01, DRB1*04:01, DRB1*07:01, DRB1*07:07,
DRB1*15:01 described earlier [17].
The peptide length was set 10 and 15 for MHC-I
and MHC-II, respectively. Default IEDB recommended
prediction method was selected as this selection tries
to use the best possible method that combines the predictions from ANN, SMM, and CombLib. The epitopes
are predicted on the basis of percentile rank; the low
percentile rank, the high binding affinity.
HLA distribution analysis

Table 2. Score obtained through alignment of sequences
Sequences

Aligned score

1:2

98.7705

1:3

99.3852

1:4

98.5656

1:5

99.3852

1:6

99.1803

2:3

98.1557

2:4

97.3361

The analysis of population coverage in the context
2:5
98.1557
of MHC polymorphism becomes typical as different HLA
2:6
97.9508
types are expressed at considerably different frequencies
3:4
97.9508
in different ethnicities. Due to the MHC dependence of
3:5
100
T-cell response, the peptides with more different HLA
binding specificities result in more population coverage
3:6
98.5656
in the geographical regions, where the peptide-based
4:5
97.9508
vaccine might be employed. The population coverage
4:6
97.7459
rate of the epitopes was calculated using the IEDB pop5:6
98.5656
ulation coverage tool (http://tools.immuneepitope.org/
tools/ population/iedb_input) [22]. Each epitope with its
binding HLA alleles was added, and different geographic
Antigenicity of identified epitopes
areas were also included in the analysis.
Both B-cell and T-cell predicted epitopes were
Peptide modelling
checked for their immunogenicity using VexiJen v2.0
B-cell and T-cell epitopes were designed using the online server (http://www.ddg-pharmfac.net/vaxijen/
program Discovery Studio 2.5. It was developed and dis- VaxiJen/VaxiJen.html).
tributed by Accelrys, USA. Discovery Studio is a software
Epitope physio-chemical property calculations
suite that has been frequently used to analyze and model
Peptide Property Calculator (https://www.genscript.
molecular structures, sequences, and other information
relevant to life science researchers. It includes utility com) server was used to determine the best solvent for
for viewing and editing the data along with the tools for the predicted peptide. The working methodology of this
server is based on its (peptide’s) amino acid sequence.
conducting the basic data analysis.
Protein-peptide interaction
Docking analyses between receptor (human HSPG)
and T-cell epitopes (predicted through IEDB) were performed using ZDOCK online server having great prediction abilities in Critical Assessment of Predicted Interactions (CAPRI). ZDOCK is authored & maintained by
ZLAB (Zhipping Weng’s Lab). It is a rigid-body molecular
docking program based on Fast Fourier Transform algorithm. It analyses all the possible binding modes in the
translational and rotational space between the two proteins and evaluates each pose on the basis of an energybased scoring function. The resulting z-scores with highest value were used as appropriate conformational pose.

Virtual scanning of toxic/non-toxic peptides and allergenicity assessment
The final epitope set was submitted to ToxinPred
server to identify the toxic/non-toxic peptides. This
server predicts the toxicity along with all the important physio-chemical properties. A quantitative matrix
was generated on the basis of probability or frequency
of amino acid at a particular position. The performance
was assessed by using 5-folds cross validation technique.
Further, the AllerHunter server was employed to analyze the allergenicity of the epitopes (http://tiger.dbs.
nus.edu.sg/AllerHunter). AllerHunter is a support vector
machine (SVM)-pair wise system that assesses the alJBUON 2018; 23(5): 1517

1518

In silico epitope prediction and HLA distribution analysis of HTLV-I

Table 3. Ramachandran Plot calculation of 3D model of Human receptor and viral protein sequences
Protein

Ramachandran plot statistics
% residues in most favored regions

% residues in allowed regions

% residues in outlier regions

Human HSPG

91.5

6.5

2.0

Japan MT-2

94.2

4.9

0.8

Caribbea HS-35

92.2

6.2

1.6

Malensia Mel5

92.8

5.8

1.4

Japan ATK-1

91.2

7.8

1.0

Zaire EL

93.2

5.4

1.4

Caribbea CH

93.6

4.7

1.6

Figure 2. Structural validation of modeled protein using RAMPAGE: (A) Human HSPG, (B) Japan MT-2, (C) Caribbea
HS-35, (D) Malensia Mel5, (E) Japan ATK-1, (F) Zaire EL, (G) Caribbea CH.
JBUON 2018; 23(5): 1518
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lergenicity and allergic cross-reactivity in the proteins.
AllerHunter predicts allergens and non-allergens with
high sensitivity and specificity, without compromising
the efficiency at the classification of proteins with similar sequences to known allergens [23].
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termine the immunogenicity of protein on the basis of overall score produced by the specific protein
sequence.
Structure validation

Once the sequences were established as immunogenic, the 3D-structures of ‘Env’ proteins were
predicted using I-TASSER. The structures were
Immunogenic protein identification and genetic vari- further validated with Ramachandran plot analysis
ability analysis
using ‘RAMPAGE’ as shown in Figure 2 and Table
The selection of the immunogen is considered 3. The I-TASSER modelled structure is depicted in
as the preliminary step of vaccine development. Figure 3.
The said selection was performed on the sequences
Identification of humoral immunity associated epitope
of all the isolates retrieved for ‘Env’ protein. The
results revealed all the isolates to be immunogenic
One of the key steps in epitope-based vaccine
(Table 1) and genetically highly conserved (Table designing is the prediction and identification of the
2). The VaxiJen v2.0 online server was used to de- B-cell epitopes in the target antigens. The ABCPred

Results

Figure 3. 3D structure modeled using I-TASSER and refined by ModRefiner. (A) Human HSPG, (B) Japan MT-2,
(C) Caribbea HS-35, (D) Malensia Mel5, (E) Japan ATK-1, (F) Zaire EL, (G) Caribbea CH.
JBUON 2018; 23(5): 1519
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database was used to obtain the B-cell epitope candidates in the ‘Env’ protein of HTLV-1. Based on
Artificial Neural Network method of the ABCPred
server, the number of epitopes identified for different isolates were as follows:
11 potential epitopes for Japan MT-2; 10 potential epitopes for Caribbea HS-35; 11 potential
epitopes for Malesia mel5; 11 potential epitopes
for Japan ATK-1; 11 potential epitopes for Zaire EL;
12 potential epitopes for Caribbea CH.
Humoral immunity associated epitopes predicted by ABCpred were in descending order of
their score, depicting the top scorer at the highest
point having the best binding affinity. Selecting the
first (top) epitope for each strain has given a total
of six epitopes. Out of the 6 B-cell epitopes, 5 had
100% sequence conservation. Therefore, a total of
two B-cell epitopes “PSQLPPTAPPLLPHSNLDHI”
and “EPSQLPPTTPPLLPHSNLDH” with score 1 at
position 180 and 179, respectively, showing highest probability to be as antigenic determinants,
were identified.

Identification of CD4+ and CD8+ epitope
MHC-II restricted CD4+ T-cells activation
plays an important role for initiating and upholding a proficient antibody response or Cytotoxic T
Lymphocytes (CTL) response. On the other hand,
MHC-I restricted CD8+ CTLs has a vital role in
combating the viral infection. Thus, comprehending the principles of T cell activation and epitopebased vaccine design directs the identification of
helper T-cell epitopes & CTL epitopes. Hence, the
helper T-cell epitopes & CTL epitopes in the ‘Env’
protein of HTLV-1 were identified using in silico
approach. Here, the immunogenic peptides, obtained with recommended methods were ranked
according to their consensus percentile rank from
SWISS-PROT proteins. The lowest percentile rank
demonstrated the best binders. Selecting the first
(lowest percentile rank) epitope for each of the 6
alleles of MHC CLASS II and 18 alleles of MHC
CLASS I has given 6 helper T-cell epitopes and 18
CTL epitopes for each of the six strains of HTLV-I
using IEDB.

Table 4. HLA distribution and population coverage analysis results
Strain

Coverage, %

Average hit

PC90

Japan MT-2 subtype A

95.15

2.21

1.23

Caribbea HS-35 subtype A

96.41

2.39

1.35

Melanesia mel5 subtype C

96.41

2.39

1.35

Japan ATK-1 subtype A

96.41

2.39

1.35

Zaire EL subtype B

96.41

2.39

1.35

Caribbea CH subtype A

96.41

2.39

1.35

Figure 4. Graphical representation of predicted epitope / HLA distribution among different isolates of HTLV-I.
JBUON 2018; 23(5): 1520
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Table 5. HSPG-peptide docking results
S. No.

Epitope

Z dock-Score

Intermolecular Hydrogen Bond

Hydrogen Bond Distance

1

LVALLLLVILAGPCI

1579.921

:LEU79:N - A:GLY12:O

3.16958

2

SSPYWKFQHDVNFTQ

1662.858

:ALA4:N - A:SER2:OG

2.15667

:TRP5:N - A:SER2:OG

2.72544

A:SER1:N - :ARG3:O

3.09156

A:SER2:N - :ARG2:O

2.7973

CLASS II (CD4+)

3

4

5

YWKFQQDVNFTQEVS

YSSYHATYSLYLFPH

PCPNLVAYSSYHATY

1612.931

1874.750

1607.413

A:SER2:N - :ARG3:O

2.05351

A:SER2:OG - :ARG2:O

3.05556

A:SER2:OG - :ARG3:O

2.37172

A:ASN12:N - :GLU126:OE1

2.85617

A:ASN12:N - :GLU126:OE2

2.95054

:TYR44:OH - A:ASP7:O

2.35794

:THR80:N - A:THR11:OG1

1.87384

:GLY182:N - A:TRP2:O

3.05172

:SER188:N - A:PHE4:O

2.76898

:SER188:OG - A:PHE4:O

2.88083

A:VAL1:N - :ASP180:OD1

1.17792

A:TRP2:N - :ASP180:OD2

2.92515

A:TRP2:NE1 - :MET171:O

2.1366

A:TRP2:NE1 - :ARG172:O

2.99427

A:TRP2:NE1 - :LYS173:O

3.124

A:LYS3:NZ - :GLU183:OE2

1.74793

A:GLN5:N - :SER188:OG

2.71964

A:VAL8:N - :TYR44:OH

3.07846

A:THR11:OG1 - :LEU79:O

2.5652

A:THR11:OG1 - :THR80:O

2.94651

A:THR7:N - :ASP48:OD1

2.26765

A:TYR8:N - :ASP48:OD1

2.16293

A:TYR8:OH - :ARG72:O

2.75544

A:SER9:N - :ASP47:OD2

2.46973

A:SER9:OG - :ASP47:OD1

2.3081

A:SER9:OG - :ASP47:OD2

1.82501

A:TYR11:OH - :TYR191:O

3.02424

:MET1:N - A:LEU5:O

3.18292

:TRP5:NE1 - A:SER7:OG

1.98532

:TRP5:NE1 - A:SER7:O

2.92805

:TYR44:OH - A:HIS12:O

3.13358

:GLY156:N - A:SER10:OG

2.83934

A:LEU5:N - :SER103:O

2.91771

A:SER10:OG - :ILE155:O

2.01553

A:HIS12:N - :TYR44:OH

3.06947

A:ALA13:N - :TYR44:OH

2.5348

Continued on the next page

JBUON 2018; 23(5): 1521

1522

S. No.
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Epitope

Z dock-Score

Intermolecular Hydrogen Bond

Hydrogen Bond Distance

SLYLFPHWIK

1666.732

:LEU79:N - A:LYS10:O

2.39997

CLASS I (CD8+)
6

7

8

LHFSKCGFPF

YHATYSLYLF

1671.469

1715.898

Population coverage of epitopes
HLA allocation varies among the diverse ethnic groups and geographic regions around the
world. Thus, while designing an effective vaccine,
population coverage must be taken into account to
cover the maximum possible populations [24]. All
the alleles in the supplementary data were identified as the best binders with the predicted epitopes
and were used to establish the population coverage for these epitopes (Figure 4). Almost complete
population coverage was found for all the putative helper T-cell epitopes and CTL epitopes in six
specified geographic regions of the world (Table 4).
JBUON 2018; 23(5): 1522

:TYR131:OH - A:LEU2:O

2.40817

:THR196:OG1 - A:LEU4:O

2.22273

:LYS197:N - A:TYR3:OH

2.85881

:LYS197:N - A:LEU4:O

2.95916

:GLU198:N - A:LEU4:O

2.28237

A:TYR3:N - :TYR131:OH

1.21732

A:TYR3:OH - :LYS197:O

2.9753

A:PHE5:N - :GLU198:OE2

2.60355

A:HIS7:N - :GLY153:O

2.41912

A:TRP8:NE1 - :GLY156:O

3.12138

:TYR44:OH - A:PHE3:O

2.54674

:SER178:OG - A:PHE10:O

2.77812

:SER178:OG - A:PHE10:OXT

1.86774

:ASP180:N - A:PHE10:O

2.83619

:SER188:OG - A:CYS6:SG

2.50789

A:SER4:N - :TYR44:OH

2.76142

A:CYS6:SG - :SER188:OG

2.50789

A:PHE10:N - :MET171:O

2.943

A:PHE10:N - :TYR179:O

2.46562

A:PHE10:N - :ASP180:OD2

1.70985

:MET1:N - A:HIS2:O

2.22991

:TRP5:NE1 - A:THR4:O

1.93176

:TYR44:OH - A:LEU9:O

3.09167

:THR101:OG1 - A:TYR1:OH

2.18107

A:TYR1:OH - :THR101:OG1

2.18107

A:LEU9:N - :TYR44:OH

2.64379

A:PHE10:N - :TYR44:OH

2.19778

Protein peptide docking and CD4+ and CD8+ epitope
screening
When selected CD4+ and CD8+ epitope (best five
based on best binding affinity; high energy score,
between receptor and epitope) for all the six strains
of HTLV-I, were analyzed, we found that several of
these epitopes had 100% sequence identity. Hence,
based on the sequence conservation, a total of eight
domains (five CD4+ & three CD8+) were screened
out to be used as helper T-cell epitopes: “YSSYHATYSLYLFPH”, “PCPNLVAYSSYHATY”, “YWKFQQDVNFTQEVS”, “SSPYWKFQHDVNFTQ”, “LVALLLLVILAGPCI”, and CTL epitopes: “SLYLFPHWIK”,
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“LHFSKCGFPF”, and “YHATYSLYLF”, which may
serve as useful diagnostic reagents for evaluating
immune response against all the strains of HTLV-I
(Figure 5 and Table 5).
Further, the peptides with strong antigenicity
are more likely to be B-cell & T-cell epitopes than
those with weak antigenicity. Hence, VaxiJen v 2.0
server (http://www.ddg-pharmfac.net/vaxijen/VaxiJen/VaxiJen.html) was used to predict the antigenic-
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ity of the selected epitopes. This tool predicts the
antigenicity of a peptide on the basis of amino acid
properties and their positions in the peptide [18].
The obtained results showed that both the
predicted B-cell epitopes had antigenic properties
and they can be crucial in eliciting the desired immune response, whereas, out of the predicted 8 Tcell epitopes, 5 (four for CD4+ and one for CD8+)
were found to be probable antigen (Tables 6 and 7).

Figure 5. Docked (Peptide-HSPG) structures generated through Discovery Studio 2.5. Epitopes having best binding
affinity (highest Z-dock-score) docked with HSPG. (A) LVALLLLVILAGPCI-HSPG, (B) SSPYWKFQHDVNFTQ-HSPG, (C)
YWKFQQDVNFTQEVS-HSPG, (D) YSSYHATYSLYLFPH-HSPG, (E) PCPNLVAYSSYHATY-HSPG, (F) SLYLFPHWIK-HSPG,
(G) LHFSKCGFPF-HSPG, (H) YHATYSLYLF-HSPG
Table 6. Humoral immunity associated epitope with their antigenic score
Position

Humoral associated epitope

Antigenic score

Antigen/Non-antigen

180

PSQLPPTAPPLLPHSNLDHI

0.5190

Antigen

179

EPSQLPPTTPPLLPHSNLDH

0.4374

Antigen

Table 7. CD4+ and CD8+ epitope with their antigenic score
Position

Allele

CD4+ and CD8+ epitope

Antigenic score

Antigen/ Non-antigen

CD4+ (CLASS II)
449-463

HLA-DRB1*01:01

LVALLLLVILAGPCI

0.3352

Non-Antigen

129-143

HLA-DRB1*04:01

SSPYWKFQHDVNFTQ

0.8936

Antigen

132-146

HLA-DRB1*04:01

YWKFQQDVNFTQEVS

0.7403

Antigen

73-87

HLA-DRB1*07:07

YSSYHATYSLYLFPH

0.5073

Antigen

66-80

HLA-DRB1*15:01

PCPNLVAYSSYHATY

0.9356

Antigen

81-90

HLA-A*03:01

SLYLFPHWIK

-0.0424

Non-Antigen

152-161

HLA-B*14:02

LHFSKCGFPF

0.1898

Non-Antigen

76-85

HLA-B*38:01

YHATYSLYLF

0.5075

Antigen

CD8+ (CLASS I)
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Among them, the highest scored antigenic Discussion
epitopes for humoral immunity associated
and CD4+ and CD8+ (MHC-II & MHC-I) were
HTLV-I is an infectious virus and causes sevPSQLPPTAPPLLPHSNLDHI, PCPNLVAYSSYHATY eral pathogenic conditions including fatal T-cell
and YHATYSLYLF, respectively.
lymphoma. Recent studies have reported that the
entry of HTLV-I in humans is mediated by the atPhysio-chemical properties of final epitope set
tachment of the viral envelope (gp46) to the human
The overall interactive property calcula- receptor HSPG. Latest advancements in the field
tion (Table 8) of most antigenic epitopes re- of bioinformatics have allowed the application of
vealed that highest scored antigenic epitopes immunomics as an alternative approach to the traPSQLPPTAPLLPHSNLDHI, PCPNLVAYSSYHATY ditional vaccine development strategy. The online
and YHATYSLYLF, were all suitable to dispense accessibility of the complete genome sequences
in the basic medium, thus, predicted antigenic has transformed the approach to in silico vaccine
epitopes (BASIC), solubilized in 10% or higher ace- development. T lymphocytes are crucial in elicittic acid solution or by adding <50 μl trifluoroacetic ing a protective immune response against various
acid (TFA) and diluted to 1 ml with deionized water. microbial infections, thus the identification and
This information can be used to make suitable dilu- selection of T-cell epitopes as vaccine targets is a
ent for their efficient use as peptide vaccine.
prerequisite task for designing the epitope-based
vaccines. The determination of B-cell epitopes is a
Toxicity and allergenicity screening of the identified crucial task for the vaccine development as well as
epitopes
for better diagnosis. Recently, synthetic peptides
The final epitope set (CD4+, CD8+ and humoral have been shown to induce antibodies reactive with
associated) with best antigenic score were further their associated sequences in the native proteins.
As a first step in defining the B- and T-cell
confirmed for their toxicity. The obtained results
are shown in Table 9. Analysis revealed that among epitopes in HTLV-I, the search of RCSB Protein
the best antigenic peptides none (epitopes) were Data Bank (http://www.rcsb.org) verified that the refound allergic against humans.
quired tertiary structures of human protein HSPG
Table 8. Analysis of Epitope Physio-Chemical property calculation
Epitopes

Chemical formula

M. Wt

Iso-Electric point

Hydrophilicity analysis
Charge

Attribute

Humoral immunity associated
PSQLPPTAPPLLPHSNLDHI

C98H154N26O28

2144.44

6.50

1

Basic

EPSQLPPTTPPLLPHSNLDH

C98H152N26O31

2190.42

5.30

0

Neutral

C64H84N12O16

1277.43

7.53

1

Basic

SSPYWKFQHDVNFTQ

C88H118N22O25

1884.02

7.54

1

Basic

YWKFQQDVNFTQEVS

C89H123N21O27

1919.06

4.19

-1

Acidic

YSSYHATYSLYLFPH

C90H117N19O24

1849.01

7.68

2

Basic

PCPNLVAYSSYHATY

C77H108N18O24S1

1701.86

7.34

1

Basic

CD8+
YHATYSLYLF
CD4+

Table 9. Toxicity analysis of predicted best antigenic epitope set
Peptide sequence

SVM score

Toxicity prediction

Hydrophobicity

Hydropathicity

PCPNLVAYSSYHATY
(CD4+ epitope)

-0.64

Non-Toxin

-0.01

-0.13

YHATYSLYLF
(CD8+ epitope)

-1.03

Non-Toxin

0.10

0.33

PSQLPPTAPPLLPHSNLDHI
(Humoral associated epitope)

-1.36

Non-Toxin

-0.04

-0.37
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and ‘Env’ protein of HTLV-I was not publicly available. The FASTA format amino acid sequences of
the above mentioned proteins were retrieved from
UniProt (http://www.uniprot.org).
The immunogenicity of each strain of HTLVI was confirmed with the help of Vaxijen online
server. The alignment of the amino acid sequences
among six strains of HTLV-I revealed the overall
identity of the structural proteins (among the isolates, ‘Env’ proteins are known to be genetically
highly conserved). Following the antigenicity confirmation, I-TASSER was employed to predict the
3D-structure. The refinement of the generated model was performed by using ModRefiner followed
by the structure validation by using RAMPAGE.
The predicted 3D-structures provided more insight
in comprehending the structure and functions of
the proteins and were found fit for the interaction
analysis.
The candidates for peptide synthesis were derived from the protein sequence with the help of
predictive computational algorithms and HLA supertypes. Among all the predicted B-cell epitopes,
selecting first (top) from each strain criterion was
followed for generating 6 epitopes. Five out of 10
epitopes were conserved, and finally we had 2 Bcell epitopes.
Helper T-cell epitopes are crucial for effective humoral and CTL responses. Although, the
response to T-cell epitope is dependent upon HLA
proteins, yet the fact is that HLA is highly polymorphic in various ethnic populations. Hence, the HLA
specificity of T-cell epitopes must be the principal
criterion for screening of the epitopes as vaccine
candidates to cover the genetically diverse human
population [25,26]. The HLA supertype concept has
a substantial role in the understanding of CD4+
and CD8+ epitope’s selection, discrimination during T-cell mediated immune response and degeneration. In the HLA supertype analysis, IEDB web
server was used to check the binding of the best
epitopes with those of HLA alleles; and 18 MHC-I
and 6 MHC-II peptides were found in all the known
genotypes, as it is established that an epitope elicits a response only if it is capable of binding a
MHC molecule in an individual. This phenomenon
is called as denominated MHC restriction of T-cell
responses. Including multiple peptides with different HLA binding specificities increases the coverage of the population targeted by the peptide-based
vaccines or diagnostics. We have performed HLA
distribution and population coverage analysis for
the predicted epitopes that showed 96.41% of the
projected population coverage with 2.39 average
numbers of epitope hits/HLA combinations recognized by the population.
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It was found that HLA specific predicted
docked peptides were highly conserved among the
six genotypes, hence, resulted a total of 8 (5 CD4+
and 3 CD8+) epitopes for all the selected genotypes. Among all the predicted humoral associated
epitopes, 2 epitopes “PSQLPPTAPPLLPHSNLDHI”
and “EPSQLPPTTPPLLPHSNLDH” were found to be
antigenically effective and among 8 T-cell epitopes,
5 epitopes i.e., 1 CD8+ “YHATYSLYLF”, and 4 CD4+
“SSPYWKFQHDVNFTQ”, “YWKFQQDVNFTQEVS”,
“YSSYHATYSLYLFPH” and “PCPNLVAYSSYHATY”
were found to be antigenically effective. Further,
among these antigenic epitopes, 1 epitope “PCPNLVAYSSYHATY” at position 66-80 had the highest
antigenic score (0.9356) ensuring maximum immune response.
Additionally, to check the biocompatibility of the
best (1 each top scorer from B-cell, MHC-II and MHC-I)
antigenic epitopes “PSQLPPTAPPLLPHSNLDHI”,
“PCPNLVAYSSYHATY” and “YHATYSLYLF” were
tested by Epitope Physio-Chemical property calculator. The analysis revealed that these epitopes
have basic attributes to dissolve in water and if not
then in 10% acetic acid; otherwise TFA (<50 μl).
These properties can be used to make a suitable
diluent to dispense the peptide vaccine. In order
to evaluate the toxicity of the final epitope set, we
employed virtual screening of the peptides using
ToxinPred server (that uses 5-folds cross validation technique). The obtained results strongly predicted that all the three epitopes were non-toxic,
non-allergic and safe for use.
The application of the predicted potential
epitopes instead of whole protein as a vaccine
has already been established and currently it is in
enormous use as the predicted epitopes are fully
capable of representing the complete antigenicity
of any protein [27]. Epitope-based vaccines have
given promising results against the highly infectious diseases such as H1N1, HIV, and Tuberculosis
[28]. These vaccines have low chance of eliciting
immune response against the self-antigens, thus
evade autoimmune response [29]. The conventional
molecular immunology techniques for the search
of immunogenic peptide to be used as vaccine candidates are exorbitantly time-taking and expensive.
Therefore, the present in silico study may help out
the experimental biologists by providing assistance in the rapid screening process to facilitate
the identification of the probable vaccine candidates. Lately, these computational approaches are
recently being used by many researchers across
the globe [30]. In silico approach reported in the
current study for T-cell epitope prediction and
population coverage analysis not only reduces the
cost in an efficient manner, but also the time and
JBUON 2018; 23(5): 1525
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efforts invested in the planning and execution of
the experiments and subsequent development of
epitope-based vaccines. The application of in silico
approaches by immunologists has helped to speedup the in vitro, in vivo and ex vivo studies by cutting
down the large epitope dataset to a smaller dataset
that warrants their experimental validation.
In conclusion, genetic variability and HLA
distribution analysis of HTLV-1 genotypes I, II,
III, IV, V and VI was done for the broader population coverage of the proposed vaccine. The
screening of the effective dominant immunogens revealed that the identified epitopes were
protective immunogens with high conservancy
and bears potential of inducing both protective
neutralizing antibodies and T-cell responses. The
obtained peptides “PSQLPPTAPPLLPHSNLDHI”,
“PCPNLVAYSSYHATY”, and “YHATYSLYLF” were
fully conserved among different isolates from far
and wide separated countries suggesting negligible antigenic drift in HTLV-1. In conclusion, the
predicted epitopes are soluble, non-toxic suitable
candidates for the vaccine development against
HTLV-1 and warrants for further investigation and
experimental validation. The prophecies made in

the current study inferred from the primary amino
acid sequence from various HTLV-I isolates would
tremendously help the researchers involved in
the experimental verification of the immunodominant epitopes that are being considered as the
fundamental to the understanding of the pathobiology of HTLV-I and its effective ATL vaccine
development.
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